Clinical trial IMMU-132-14
Open-label Rollover Study to Evaluate Long-Term Safety in Subjects with Metastatic Solid Tumors that are Benefiting from Continuation of Therapy with Sacituzumab Govitecan
| Cancers | |
|---|---|
| Organ | Breast |
| Trial status | Trial closed for recruitment |
| Investigator | |
| Trial type |
Interventional with experimental drug
|
| Phase | Trial phase 3 |
| Academic trial | Non |
| Sponsor | Immunomedics |
| EudraCT Identifier | 2019-004868-22 |
| ClinicalTrials.gov | https://clinicaltrials.gov/ct2/show/NCT04319198 |
| Last update |